The two partners will pool their expertise to maximize their
investments in technological development and accelerate the deployment
of innovative cancer treatments.
Created as part of Cancer Plan 1 in 2003 and certified by the National Cancer Institute, CANCEROPOLE NORD-OUEST (CNO) aims to promote the economic exploitation of research results from sixty-three certified research teams (Inserm, CNRS, universities) collaborating with forty-nine clinical departments and hospital laboratories, by directing them to the appropriate structures and programs.
The development of public/private partnerships is also promoted in close collaboration with the necessary local, national, and/or European partners.
Created in July 2012, SATT Nord aims to facilitate the transfer of technology and knowledge from public research to businesses. Supported by the research institutions that are shareholders in the territories it covers (Hauts-de-France and Champagne-Ardenne), it has access to the skills and inventions of public researchers and relies on dedicated professional teams to identify and evaluate these inventions. Like other SATTs in the region, it has a maturation fund and protects, finances, and supports these innovation projects until they are adopted by companies, bearing the technological and financial risk.
Although the two organizations have already been collaborating for several years through the research teams that make up CANCEROPOLE NORD-OUEST, they wished to formalize their relationship by signing a partnership agreement on Friday, June 21, 2019.
This will give researchers greater visibility of stakeholders and a single point of entry, the CNO, for promoting cancer research projects. CANCEROPOLE NORD-OUEST and SATT NORD will work together to improve the economic added value of the CNO teams' research programs through:
– early detection of innovative projects with high added value and their positioning in relation to the competition and the need for therapeutic solutions, thanks to monitoring over a three-year period after the end of funding for projects financed under the CNO's Emergence and Structuring calls for proposals;
– organizing training courses to raise awareness of research valorization among research staff in order to familiarize them with the missions, challenges, and tools of research valorization;
– Concerted pre-maturation, in order to protect research results by filing and maintaining intellectual and industrial property rights, strengthen proof of concept, and maximize the chances of generating industrial interest that will take over development
– the setting up, financing, and management of maturation projects reviewed and validated by SATT Nord in accordance with its process;
– support for transfer, in order to facilitate access for manufacturers in the health sector to technologies owned by SATT Nord, CANCEROPOLE NORD-OUEST acts as the link between SATT Nord and MATWIN, a subsidiary of the UNICANCER group (which brings together all French cancer centers), a national program supporting projects focused entirely on innovation in oncology.
The Canceropôle and SATT Nord have been working together for several years now to maximize the chances of technology transfer and enable patients to benefit from new innovations in cancer treatment. Among the projects funded and monitored by SATT Nord and Cancéropole Nord-Ouest, two have led to the creation of a startup. The Gal 9 project, focusing on a new anti-tumor strategy, gave rise to the startup H-Immune, and the Spidermass project, a real-time in vivo molecular analysis device
for intraoperative use, will also be developed through the creation of a future startup in the coming months." Christine USEILLE, Regional Director, SATT Nord Lille